Evidence map›Paper›PMID 38106151›Full record

ArticlemedRxiv : the preprint server for health sciences2023

Genomic and immune determinants of resistance to anti-CD38 monoclonal antibody-based therapy in relapsed refractory multiple myeloma.

Bachisio Ziccheddu, Claudia Giannotta, Mattia D'Agostino, Giuseppe Bertuglia, Elona Saraci, Stefania Oliva, Elisa Genuardi, Marios Papadimitriou, Benjamin Diamond, Paolo Corradini and 8 more

Registry-linked trialOpen access · greenAbstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in medRxiv : the preprint server for health sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03848676 (Genomic and Phenotypic Determinants of Resistance to Immunotherapies in Multiple Myeloma), which is not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03848676 completednot on this map

Genomic and Phenotypic Determinants of Resistance to Immunotherapies in Multiple Myeloma

TypeobservationalSponsorUniversity of Turin, ItalyRan2018 to 2024Enrolled40ConditionsMultiple MyelomaArmsEvaluation of patients resistance to immunotherapies in Multiple Myeloma
3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 3 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

18 authors at 6 institutions in 2 countries.

Bachisio Ziccheddu
Claudia Giannotta
Mattia D'Agostino
Giuseppe Bertuglia
Elona Saraci
Stefania Oliva
Elisa Genuardi
Marios Papadimitriou
Benjamin Diamond
Paolo Corradini
David Coffey
Ola Landgren
Niccolò Bolli
Benedetto Bruno
Mario Boccadoro
Massimo Massaia
Francesco Maura
Alessandra Larocca
Azienda Ospedaliera Citta' della Salute e della Scienza di Torino · ITUniversity of Miami · USAzienda Sanitaria Ospedaliera S.Croce e Carle Cuneo · ITFondazione IRCCS Istituto Nazionale dei Tumori · ITUniversity of Milan · ITUniversity of Turin · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Anti-CD38 antibody therapies have transformed multiple myeloma (MM) treatment. However, a large fraction of patients inevitably relapses. To understand this, we investigated 32 relapsed MM patients treated with daratumumab, lenalidomide, and dexamethasone (Dara-Rd; NCT03848676 ). Whole genome sequencing (WGS) before and after treatment pinpointed genomic drivers associated with early progression, including

Identifiers

PMID38106151
PMCPMC10723485
OpenAlexW4389346605

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.